Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study of the mTOR Inhibitor Temsirolimus(CCI-779) in Patients With CA125 Only Relapse of Ovarian Cancer. A Phase II Study by the Hellenic Cooperative Oncology Group.

NCT00926107 is registered in ClinicalTrials.gov with Hellenic Cooperative Oncology Group as lead sponsor.

NCT NCT00926107
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00926107 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study of the mTOR Inhibitor Temsirolimus(CCI-779) in Patients With CA125 Only Relapse of Ovarian Cancer. A Phase II Study by the Hellenic Cooperative Oncology Group.
Lead sponsor
Hellenic Cooperative Oncology Group
Phase
Phase 2
Overall status
Terminated
Start date
June 30, 2009
Completion date
October 31, 2011
Enrollment
9 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian cancer